BreAst Cancer and Cardiotoxicity Induced by RAdioTherapy: the BACCARAT Study

Breast Cancer Clinical Trial

— BACCARAT  

Official title:

Early Detection and Prediction of Cardiotoxicity in Radiotherapy-treated Breast Cancer Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02605512
• Other study ID #: IRSN_2015-A00990-49
• Status: Completed
• Phase: N/A
• Start date: October 2015
• Est. completion date: February 2020

Study information

• Verified date: November 2023
• Source: Institut de Radioprotection et de Surete Nucleaire
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Breast radiotherapy RT used until the 1990s was clearly responsible for increased mortality due to long term cardiac complications. Since the 2000s, improvements have appeared in dose distributions to organ at risks such as heart, but now, little is known on the risk of potential cardiac impairment in this population, in particular for chemotherapy naive patients. Based on the state that clinically detectable cardiotoxicity is generally preceded by subclinical cardiac dysfunctions, the aim of the BACCARAT study (BreAst Cancer and Cardiotoxicity induced by RAdioTherapy) is to evaluate whether adjuvant 3DCRT induces cardiac toxicity that could be detected in the first two years after treatment based on a global approach with repeated analysis of subclinical functional and anatomical cardiac lesions in myocardial and coronary levels and circulating biomarkers.

Description:

BACCARAT study consists in a monocentric prospective cohort study that will finally include 120 women treated with adjuvant RT for breast cancer in the Clinique Pasteur in Toulouse, and followed for 2 years after RT.

Women aged 50 to 70 years, treated for breast cancer and for whom adjuvant 3DCRT is indicated, without chemotherapy are eligible for the study.

Baseline and follow-up include measures of functional myocardial dysfunction based on 2D-speckle tracking echocardiography, anatomical coronary lesions based on Coronary computed tomography angiography, and a wide panel of circulating biomarkers. Absorbed doses is evaluated for whole heart and for each different parts of heart, in particular coronary arteries.

Analysis on occurrence and evolutions of subclinical cardiac lesions and biomarkers will be performed and completed with dose-response relations with absorbed doses of different heart segments.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 118
• Est. completion date: February 2020
• Est. primary completion date: February 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 50 Years to 70 Years

Eligibility

Inclusion Criteria:

• Age between 50 and 70 years

• Women surgically treated for left or right breast cancer and for whom adjuvant treatment is radiotherapy with irradiation of the breast or chest wall irradiation and possibly ganglion chains,

• Adjuvant radiotherapy with 3DCRT performed in Clinique Pasteur Toulouse

• WHO performance status ECOG - Eastern Cooperative Oncology Group (index normally used to describe the patient's condition) = 0 or 1

• Being volunteer to participate in the study and have signed the consent form

Exclusion Criteria:

• Indication of adjuvant chemotherapy

• Clinically or radiologically detectable metastasis

• Personal history of coronary artery disease or myocardial disease

• Personal history of breast cancer or other cancer requiring radiotherapy to the thorax

• Patient with controlled infection or severe disease and / or non-hazardous to their participation in the study

• Contraindications to injection of iodinated contrast (for CCTA): pregnancy, renal failure, allergy.

• Pregnancy, lactation

• Abnormal echocardiography before radiotherapy:

• LVEF <50%

• Longitudinal strain> - 16%

• Longitudinal strain rate <1% / s

• Abnormal wall motion

• CCTA before radiotherapy showing that therapeutic management is required (coronary-artery calcium (CAC) score>600)

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms
• Cardiac Toxicity
• Cardiotoxicity

Intervention

Other:
• Subclinical cardiac lesions and biomarkers
Functional myocardial dysfunction based on 2D-speckle tracking echocardiography, Anatomical coronary lesions based on Coronary computed tomography angiography, a panel of circulating biomarkers based on blood samples and plasma

Locations

Country	Name	City	State
France	Clinique Pasteur	Toulouse

Sponsors (4)

Lead Sponsor	Collaborator
Sophie JACOB	Clinique Pasteur, Institut de Radioprotection et de Surete Nucleaire, Institut National de la Santé Et de la Recherche Médicale, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients with decreased myocardial function assessed by echocardiography	Number of patients with a decrease in the mean strain or strain rate measured from the echocardiography of the order of 5% between the measurement before RT and 24 months after RT	2 years after 3DCRT (baseline measures performed before radiotherapy)
Primary	Number of patients with increased coronary plaques assessed by CT coronary angiography	Number of patients with an increase of the average index of coronary plaques measured from the CT coronary angiography in the order of 15% between the measurements before RT and 24 months after RT	2 years after 3DCRT (baseline measures performed before radiotherapy)
Secondary	Decrease in the strain or strain rate		6 months after 3DCRTand 2 years after 3DCRT (baseline measures performed before radiotherapy)
Secondary	Modification in series of circulating biomarkers of cardiac lesions	Classical biomarkers of cardiac injury: C-reactive protein, Troponin I, B-type natriuretic peptide (NT-Pro BNP), beta2-Microglobulin, Galectin 3 / Inflammatory cytokines: Interleukin 6, Interleukin 8, Interleukin 18, TNF-a / Endothelial activation and dysfunction: sVCAM,-1 , s-ICAM-1, E-selectin, P-selectin , vWF, PAI-1, Fibrinogen , Thrombomodulin, TGF-ß1 / Microparticles: CD14, CD31, CD41, CD3, CD235a / microRNAs : miR-1, miR-133, miR-208, miR-499, miR-126, miR-130, miR-145, miR-181, miR-150, miR-155, miR-223, miR-17, miR-18, miR-22, miR-34, miR-92, miR-140, miR-182, miR-199, miR-423, miR-590	5 weeks after initiation of 3DCRT (corresponding to the end of 3DCRT sessions), 6 months after 3DCRTand 2 years after 3DCRT (baseline measures performed before radiotherapy)
Secondary	Correlation between the absorbed radiation dose by the whole heart and different structures of the heart and measurements of strain and strain rate and indices of coronary plaques		2 years